AHA advertorial: 340B program advances health for patients and communities
As drug prices continue to rise, the 340B drug pricing program continues to help hospitals expand access to comprehensive health services, including lifesaving prescription drugs for those in need who may not be able to afford them, writes AHA President and CEO Rick Pollack in the Wall Street Journal.
“It is in the best interest of all to keep the 340B program strong so that our nation’s patients and communities can continue to receive the high-quality care and services on which they depend,” the advertorial adds.
Related News Articles
Headline
The AHA May 25 published a report on the 340B Drug Pricing Program, its history and value to hospitals and patients, and details on 340B contract pharmacy…
Headline
The House Energy and Commerce Subcommittee on Health May 17 considered a series of health care bills, including a number focused on provisions that would…
Headline
The AHA strongly opposes legislation that would lead to additional site-neutral payment cuts and threaten access to patient care, Ashley Thompson, AHA senior…
Headline
More than 1,000 executive leaders from the nation’s top hospitals and health systems convened at the 2023 AHA Annual Membership Meeting, April 23-25 in…
Headline
The AHA, joined by the Arkansas Hospital Association and 340B Health, late Friday filed an amicus brief in the U.S. Court of Appeals for the 8th Circuit…
Headline
The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug…